The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens

D Serruto, MJ Bottomley, S Ram, MM Giuliani… - Vaccine, 2012 - Elsevier
Neisseria meningitidis is a major cause of endemic cases and epidemics of meningitis and
devastating septicemia. Although effective vaccines exist for several serogroups of …

Looking beyond meningococcal B with the 4CMenB vaccine: the Neisseria effect

Y Ruiz García, WY Sohn, KL Seib, MK Taha… - npj Vaccines, 2021 - nature.com
Infections with Neisseria meningitidis and Neisseria gonorrhoeae have different clinical
manifestations, but the bacteria share up to 80–90% genome sequence identity. The …

Meningococcal B vaccine (4CMenB): the journey from research to real world experience

R Rappuoli, M Pizza, V Masignani… - Expert Review of …, 2018 - Taylor & Francis
Introduction: Neisseria meningitidis serogroup B (MenB) is the most common cause of
bacterial meningitis in many industrialized countries and occurs at any age. The highest …

Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease

LK McNeil, RJ Zagursky, SL Lin, E Murphy… - Microbiology and …, 2013 - journals.asm.org
Neisseria meningitidis is a Gram-negative microorganism that exists exclusively in humans
and can cause devastating invasive disease. Although capsular polysaccharide-based …

Meningococcal carriage evaluation in response to a serogroup B meningococcal disease outbreak and mass vaccination campaign at a college—Rhode Island, 2015 …

HM Soeters, M Whaley… - Clinical Infectious …, 2017 - academic.oup.com
Background. Serogroup B meningococcal disease caused 7 US university outbreaks during
2013–2016. Neisseria meningitidis can be transmitted via asymptomatic nasopharyngeal …

Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles

X Bai, J Findlow, R Borrow - Expert opinion on biological therapy, 2011 - Taylor & Francis
Introduction: Meningococcal infection is a major cause of morbidity and mortality worldwide.
Infection with Neisseria meningitidis is most common in young children, teenagers and …

The important lessons lurking in the history of meningococcal epidemiology

R Borrow, J Findlow - Expert Review of Vaccines, 2024 - Taylor & Francis
Introduction The epidemiology of invasive meningococcal disease (IMD), a rare but
potentially fatal illness, is typically described as unpredictable and subject to sporadic …

Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba®)

A Gandhi, P Balmer, LJ York - Postgraduate medicine, 2016 - Taylor & Francis
Neisseria meningitidis is a common cause of bacterial meningitis, often leading to
permanent sequelae or death. N. meningitidis is classified into serogroups based on the …

First use of a serogroup B meningococcal vaccine in the US in response to a university outbreak

LA McNamara, AM Shumate, P Johnsen… - …, 2015 - publications.aap.org
BACKGROUND: In 2013–2014, an outbreak of serogroup B meningococcal disease
occurred among persons linked to a New Jersey university (University A). In the absence of …

Emerging experience with meningococcal serogroup B protein vaccines

D Toneatto, M Pizza, V Masignani… - Expert review of …, 2017 - Taylor & Francis
Introduction: The successful development of two broadly protective vaccines targeting
Neisseria meningitidis serogroup B (MenB); 4CMenB and rLP2086, is the most significant …